TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04093271

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest-ZZZ
Description: A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest-ZZZ
Description: A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rest-ZZZ
Description: A dietary supplement containing melatonin, valerian root, chamomile, passion flower, GABA, hawthorn berry, and lemon balm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator - Diphenhydramine HCl
Description: DIN 02229960 encapsulated for blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator - Diphenhydramine HCl
Description: DIN 02229960 encapsulated for blinding purposes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Comparator - Diphenhydramine HCl
Description: DIN 02229960 encapsulated for blinding purposes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active ingredients

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: No active ingredients
Study: NCT01356095

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Knowledge translation intervention
Description: Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Palm-Plus
Description: Clinical guideline and training approach, designed for mid-level healthworkers.
Study: NCT00048152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: As prescribed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral
Description: Low dose (target trough level 50-100ng/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral
Description: Low dose (target trough level 50-100ng/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoral
Description: Standard dose (target trough level 150-300ng/mL)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zenapax
Description: 2mg/kg iv first dose, then 1mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zenapax
Description: 2mg/kg iv first dose, then 1mg/kg every 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1g po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1g po bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil [CellCept]
Description: 1g po bid
Study: NCT02189668

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antibiotics only (Zosyn then Augmentin)
Description: Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
Study: NCT02303665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The dual therapy
Description: TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The triple therapy
Description: TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
Study: NCT02392780

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Oral cannabidiol at a dose of 150 mg BID up to 90 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: IV methylprednisolone 2 mg/kg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitor
Description: cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
Study: NCT02092753

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard diet (SD)
Description: Nutrition intervention following the recommendations of the germans society for nutrition (DGE)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 1: Ketogenic diet (KD).
Description: Nutritional intervention: recommendations to follow a ketogenic diet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 2: Low glycämic and insulinemic diet (LOGI)
Description: Nutritional intervention: patients were instructed to follow the LOGI diet regimen
Study: NCT01075048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab 500 mg/ m\^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irinotecan
Description: 60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 60 minutes after cetuximab, Irinotecan 180 mg/m\^2 intravenous infusion over 30 - 90 minutes. Administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Study: NCT02433769

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TOFscan
Description: Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TOF-Watch-SX
Description: Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
Study: NCT01364155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIM-0705

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Study: NCT04510272

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aloud Real-time Reading of ICU Diaries
Description: Standard ICU diaries will be read aloud in real time daily to patients by ICU nurses/therapists/family members
Study: NCT06609993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue urapidil administration
Description: urapidil (Ebrantil 25, Takeda PHARMA, Japan) in a dose of 10 mg will be administered intravenously when DAP \> 110 mmHg or SAP \> 200 mmHg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue urapidil administration
Description: urapidil (Ebrantil 25, Takeda PHARMA, Japan) in a dose of 10 mg will be administered intravenously when DAP \> 110 mmHg or SAP \> 200 mmHg
Study: NCT00104052

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b (PEG2b) (SCH 54031)
Description: PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (SCH 18908)
Description: 15 mg/kg/day for up to 48 weeks
Study: NCT01195649

Intervention type: DRUG
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Patients under daily life treatment according to local drug information
Study: NCT06609993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous rescue ephedrine administration
Description: ephedrine (Ephedrinum Sulfuricum WZF, POlfa Warsawa, Poland) in a dose of 10 mg will be administered intravenously when DAP \< 50 mmHg or MAP \< 65 mmHg
Study: NCT04212429

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Product
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Product
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Product
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic Product
Description: Levofloxacin hydrate, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic Solution
Description: Moxifloxacin hydrochloride, an aqueous ophthalmic solution, to be given one drop at a time, 4 times daily for 3 days pre-operatively and one drop on the day of operation.
Study: NCT01433159

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HP011-101 (Xenaderm Ointment)
Description: The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
Study: NCT04161391

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPX-0046
Description: Oral TPX-0046 capsules
Study: NCT00618293

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haemate HS
Description: intravenous infusion of Haemate (dosage dependent on body weight)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: NaCl-solution
Description: intravenous infusion of 0.9%NaCl-Solution
Study: NCT03659344

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vicryl plus
Description: Using vicryl sutures which coated with triclosan (antibiotic)
Study: NCT00997334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Study: NCT01287936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623
Description: SB623, a modified stem-cell product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623
Description: SB623, a modified stem-cell product

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB623
Description: SB623, a modified stem-cell product
Study: NCT04208893

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: See description of Arms

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: See description of Arms
Study: NCT02402400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sub Lingual Ticagrelor
Description: 180mg sub-lingual ticagrelor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sub Lingual Ticagrelor
Description: 180mg sub-lingual ticagrelor
Study: NCT03713463

Intervention type: OTHER
Intervention: Oral Nutritional Supplement (ONS)
Description: Per standard of care (SOC)
Study: NCT03316846

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Delivered Cognitive Behavioral Therapy
Study: NCT00785083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTY720

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03746496

Intervention type: DIAGNOSTIC_TEST
Intervention: point-of-care laboratory analysis
Description: POC analysis with i-STAT POC analyser from the intraosseous and arterial blood
Study: NCT00947206

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LHWO about CRC
Description: 2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition Education + CRC brochure
Description: Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
Study: NCT00560963

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Study: NCT02047578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study: NCT03037632

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Heart Talk Booklet
Study: NCT00266708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risedronate
Description: risedronate 35 mg weekly

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Risedronate Placebo 35 mg weekly
Study: NCT00419705

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: NeuroThera® Laser System
Description: Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroThera® Laser System
Description: Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
Study: NCT02750631

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Triple Therapy
Description: The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
Study: NCT02695069

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Random Placenta Margin Incision
Description: A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
Study: NCT04577872

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training
Description: The treatment for the sitting group comprised 8 sessions, with a 1-hour combined pelvic floor muscle training (cPFM-T) session each week in a group and 15 minutes of individual home training, six times a week for a total of 8 weeks of treatment. All training sessions comprised warming-up, gradual muscle strengthening and relaxation exercises. In the study, before and after the training programme, we used a self-administered questionnaire.We measured changes in pelvic floor muscle activity with a vaginal surface electromyographic instrument. We performed the transversus abdominis measurements at the same time as the vaginal measurements and pelvic floor muscle tasks.
Study: NCT01548404

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection altered between back of arms, abdomen and upper thighs.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab
Description: Subcutaneous injection altered between back of arms, abdomen and upper thighs.
Study: NCT01905696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine
Study: NCT03468088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hand grip strengthening
Description: Handgrip strengthening exercises will be added to the experimental group. This exercise is chosen based on literature review of EMG and biomechanical studies. Adjustable heavy grip hand gripper will be used as handgrip resistance at 10 repetitions maximum (RM). The exercise will be performed in standing position the patient's back will be rested in a wall, arm at 30º abduction, 60º abduction 90º abduction \& with 90º ER. In this positions, the patient will be performed 3 sets of 10 squeezes each at a 1-minute interval.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional treatment
Description: Ultrasound therapy will be used to treat both groups. Ultrasound will be applied; while the patient will be seated in an adjustable chair with back support, feet on the floor. The chair will be positioned beside a table. The patient's shoulder will be rested on the table beside the body and elbow will be flexed at 90°. A round-headed probe will be used that is put in direct contact with the patient's skin over the shoulder joint. Ultrasound gel will be used on all surfaces of the head in order to reduce friction and assist in the transmission of the ultrasonic waves.
Study: NCT02519725

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ICU diary
Description: The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
Study: NCT03952819

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sclerostin
Description: blood samples obtained

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sclerostin
Description: blood samples obtained

Intervention type: DIAGNOSTIC_TEST
Intervention: serum sclerostin
Description: blood samples obtained